Peptides for Skin: What the Human Evidence Supports

Search for peptides for skin and you get two categories of thing presented as one. On one side, cosmetic ingredients you rub on. On the other, injectable compounds that alter pigment systemically. They share a word and almost nothing else, including the amount of human evidence behind them. This guide separates them, and names the one melanocortin peptide that regulators have actually approved.

Key takeaways#

• Most skin peptides are regulated as cosmetics, not medicines. That is a statement about the regulatory pathway, not about whether they work: cosmetic ingredients are not required to demonstrate clinical efficacy before sale.
• The best-evidenced topical peptide is GHK-Cu, a copper-binding tripeptide discovered in 1973. Plasma levels fall from around 200 ng/mL at age 20 to roughly 80 ng/mL by age 60.
• Delivery is the central problem, not potency. GHK-Cu is strongly hydrophilic (logD about -2.49), so it does not cross the epidermis well. The trial with the largest effect used a nano-carrier, and its authors attribute the result to the carrier.
• One melanocortin peptide is genuinely approved: afamelanotide (Scenesse). EMA authorised it on 22 December 2014 under exceptional circumstances, and the FDA approved it in 2019. The indication is erythropoietic protoporphyria, a rare light-intolerance disease. It is not a tanning product.
• Melanotan II is a different compound with a different status. It is not approved anywhere as a medicine, and it is scheduled for FDA advisory committee review before the end of February 2027.

The category splits in two before any evidence question#

The useful first question is not "does this peptide work" but "what is it, legally and physically". Two answers, and they behave differently.

Topical cosmetic peptides are ingredients in creams and serums. In the EU and Norway they sit under the Cosmetics Regulation, which governs safety and labelling. It does not require proof of clinical efficacy before sale. That is why a serum can advertise visible results on the strength of a manufacturer's own consumer panel. It is a lower bar than a medicine clears, and knowing that is most of what a reader needs.

Systemic peptides that act on pigment are a different animal. They bind melanocortin receptors and change melanin production through the body's own signalling, which is a pharmacological effect. Where those exist as approved products, they are prescription medicines with specialist administration requirements.

Conflating the two is the single most common error in this category. A copper tripeptide in a face cream and a melanocortin agonist implant are not comparable interventions, and neither the evidence nor the risk transfers between them.

GHK-Cu is the best-evidenced topical peptide, and the evidence has a catch#

GHK, glycyl-L-histidyl-L-lysine, was isolated in 1973 from human plasma. It binds copper readily, and the resulting complex is what cosmetic formulators use. It occurs naturally in plasma, saliva and urine, and plasma concentration declines with age from roughly 200 ng/mL at 20 to about 80 ng/mL at 60.

The mechanism is well described. Studies have shown GHK-Cu stimulates collagen and elastin production by dermal fibroblasts and modulates matrix metalloproteinases alongside their tissue inhibitors, which is the balance that governs whether skin matrix is being built or broken down.

The human data is genuine but small. A randomised, double-blind, split-face trial in 40 women aged 40 to 65 ran GHK-Cu in a lipid nano-carrier against a vehicle serum and against a commercial product containing Matrixyl 3000, itself a lipophilic GHK derivative. Over eight weeks the GHK-Cu serum reduced wrinkle volume by 31.6 percent relative to the Matrixyl product (p equals 0.004), and by 55.8 percent relative to the vehicle (p less than 0.001), with wrinkle depth down 32.8 percent (p equals 0.012).

Now the catch, and it is the authors' own. GHK-Cu has a logD of about -2.49, meaning it is strongly hydrophilic and does not readily cross the epidermal barrier. The trial used a nano-carrier specifically to get it through, and the paper concludes that it was the carrier that drove the difference rather than the formulation alone. The active ingredient is not the whole product. A serum listing copper tripeptide-1 on the label tells you nothing about whether any of it reaches dermal fibroblasts.

Note also that much of the enthusiastic GHK-Cu literature traces to Loren Pickart, who discovered the peptide in 1973 and authors many of the reviews. That does not make the work wrong. It does mean the review layer and the discovery layer are not independent of each other, which is worth knowing when a claim appears in five places that all cite the same person.

For the deeper treatment of GHK-Cu including dosing and reconstitution, Klarovel's complete guide to GHK-Cu goes considerably further than this pillar does, and the regulatory position in Norway is covered separately.

Afamelanotide is the approved melanocortin peptide, and it is not a tanning product#

This is where the category gets genuinely interesting, because one melanocortin peptide has cleared both major regulators.

Afamelanotide, sold as Scenesse, is a synthetic 13-amino-acid analogue of alpha-melanocyte stimulating hormone that binds predominantly to the melanocortin-1 receptor. It makes skin cells produce eumelanin, the brown-black pigment. So far that sounds exactly like the tanning peptides sold online. The differences are the whole story.

Two details on the approval are worth stating plainly, because they cut against overreading it. The EMA authorised Scenesse under "exceptional circumstances", a route used when complete efficacy and safety data cannot reasonably be obtained, here because the disease is rare. The CHMP also noted that the additional time patients could spend in sunlight was small, and weighed quality of life and unmet need in reaching a positive opinion. Scenesse also lost its orphan designation in December 2024 at the end of its ten-year market exclusivity.

So the honest summary is that a melanocortin peptide has been approved, for a rare photosensitivity disease, as a specialist-administered implant, on an exceptional-circumstances basis. That is a real and interesting regulatory fact. It is not evidence that injecting a related compound for a tan is a studied intervention, and the Melanotan II situation in Norway is a separate question with its own answer.

• Melanotan 2 in Norway: Law, Risks, and Safer Tan Options: What research shows about Melanotan 2, why DMP has not approved it in Norway, the melanoma case reports, and evidence-based pigmentation alternatives.

What the rest of the topical peptide market actually is#

Research suggests the effect of most topical actives is delivery-limited rather than potency-limited. Beyond GHK-Cu, most named peptides in skincare are signal peptides or neurotransmitter-inhibiting peptides sold as cosmetic actives. Matrixyl 3000 appears frequently and is, per the trial above, a lipophilic GHK derivative combining GHK with palmitic acid, which is a delivery solution to the same hydrophilicity problem.

The pattern to hold onto is that these are formulation ingredients competing on delivery as much as on the molecule. When a serum outperforms another serum, the difference is often the carrier system, the concentration, and whether the peptide survives the formulation, rather than the peptide identity on the label.

That is also why cross-product comparisons are difficult in this category and why Klarovel does not publish a ranked list of skin peptides. The variable that determines the outcome is usually not the one printed on the box.

Where this leaves someone evaluating a skin peptide#

The category rewards a specific kind of scepticism. Ask which regulatory pathway a product sits on, because cosmetic and medicine are different bars. Ask how the peptide is delivered, because with GHK-Cu the carrier appears to matter more than the molecule. And treat the existence of one approved melanocortin implant for a rare disease as what it is, a genuine approval with a narrow indication, rather than as validation for anything sold for tanning.

Klarovel's position on this category is that the biology is real and the marketing runs well ahead of it. Both halves of that are worth saying. Complete the Klarovel questionnaire to see what the engine recommends from a full health profile rather than from an ingredient list.